Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Supplementary Table 3 Distribution of Additional Baseline Sociodemographic and Medical Factors Included in Cohorts of Medicare Ben- eficiaries Initiating Warfarin, Dabigatran, Rivaroxaban, or Apixaban for Nonvalvular Atrial Fibrillation from 2010-2015 Characteristic, % Warfarin (n = 183,318) Dabigatran (n = 86,198) Rivaroxaban (n = 106,389) Apixaban (n = 73,039) Maximum Pairwise SMD Prior to Weightin g * Low income 18.1 19.0 16.1 15.6 0.09 Geographic region Northeast 19.6 20.2 18.6 18.3 0.05 South 41.2 41.9 42.9 45.6 0.09 Midwest 22.7 21.1 21.5 20.8 0.04 West 16.6 16.8 16.9 15.2 0.05 Rural metropolitan statistical area 24.0 23.6 22.3 23.6 0.04 Medical comorbidities Alcohol abuse 1.8 1.8 2.1 1.9 0.02 Anemia 21.5 20.1 18.9 20.5 0.06 Chronic liver disease 1.9 1.8 2.0 2.1 0.02 COPD 20.1 18.6 18.9 19.2 0.04 Dementia 3.9 3.5 3.6 3.4 0.03 Gout 5.9 5.5 5.3 6.1 0.04 Malignancy 23.1 22.7 23.4 23.9 0.03 Peripheral vascular disease 17.7 16.8 16.0 17.2 0.05 Other medical conditions Home health care 10.6 9.5 8.8 9.7 0.06 Home oxygen 8.2 7.4 7.2 7.7 0.04 Wheelchair use 2.3 2.3 1.8 1.7 0.04 Hospitalizations (nonbleeds) 38.0 36.9 37.6 37.8 0.02 Emergency department visits in past 0-30 days (n) 0 87.1 88.6 84.8 85.9 0.11 1 11.5 10.3 13.6 12.7 0.10 ≥ 2 1.4 1.1 1.6 1.4 0.04 Emergency department visits in past 31-183 days (n) 0 83.7 84.7 84.4 82.2 0.07 1 12.6 12.0 12.3 13.8 0.05 ≥ 2 3.7 3.4 3.4 4.1 0.04 Medication use Corticosteroids 15.8 14.7 16.3 16.9 0.06 Thyroid replacement 19.7 19.2 18.7 20.2 0.04 Prescriber characteristics Age group, y < 40 18.3 17.5 19.4 20.4 0.07 40-59 60.7 62.2 60.8 60.3 0.05 ≥ 60 19.8 18.6 19.0 18.4 0.04 Unknown 1.2 1.7 0.9 0.9 0.07 Female 19.6 17.0 19.1 19.8 0.07 COPD = chronic obstructive pulmonary disease. *SMD = Standardized mean difference. The maximum SMD among all pairwise comparisons is shown for each covariate prior to inverse probability of treatment weighting. Graham et al Comparative Safety and Effectiveness of Anticoagulants in Atrial Fibrillation 9.e2